You will be a key intermediary between our Penzberg Team and the broader Foundation Medicine Team in the USA.
You will facilitate the study intake process with partner/collaborator, evaluate feasibility of study with internal stakeholders and obtain FMI approval to support clinical trials.
You will manage the implementation, on-time execution and conduct of FMI support of clinical studies, including the management of milestones, timelines and deliverables, development and management of budget/finances, sample forecasting and invoicing, and management of resources.
You will build and maintain relationships with internal and external stakeholders and provide study updates as needed to Clinical Operations and biopharma leadership.
You support Clinical Operations initiatives to improve study management and data management processes.
Your qualification:
You hold a bachelor’s degree in a scientific field or 4+ years of experience in clinical trial or data management roles in lieu of a degree, AND you are able to work closely with internal and external teams to ensure quality of our FMI product.
2+ years of clinical trial or data management experience in a professional life science environment, masters or advanced degree in a business or scientific discipline.
Demonstrated history of successfully managing multiple concurrent initiatives and maintaining one’s own workflow in a fast-paced, dynamic environment.
Demonstrated evidence of success working in a cross-functional environment; able to build strong relationships.
You are fluent in English and ideally in German
Development opportunities and benefits:
You can expect a high degree of independence and a flexible working environment.
We stand for sincere and trust-based interaction with each other.
Your personal and professional development is very important to us.
All the advantages of a familiar work environment while being embedded in a large, global company.
We are a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.